
- /
- Supported exchanges
- / US
- / BMXMF.PINK
bioMérieux S.A (BMXMF PINK) stock market data APIs
bioMérieux S.A Financial Data Overview
bioMérieux S.A. develops and markets in vitro diagnostic solutions for infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It offers CHROMID RANGE, a chromogen culture media; RAPIDEC CARBA NP biochemical test for the detection of carbapenemase producing bacteria; air, surface, and water monitoring systems; BACT/ALERT VIRTUO or 3D, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system; BIOFIRE SPOTFIRE Lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated identification and antimicrobial susceptibility testing system; API RANGE standardized ID strips; VITEK REVEAL Rapid AST system; ETEST gradient method on culture media; BIOMERIEUX EPISEQ CS whole genome sequencing solution for epidemiologic monitoring; and VIDAS, a specific marker of severe bacterial infections/sepsis. It also develops Biomérieux vision suite, a software that provides information to support diagnosis and clinical decision making; culture media and associated instruments; ARGENE that provides PCR tests for diagnosing viral respiratory diseases; EMAG system and NUCLISENS extraction reagents for DNA and RNA extraction; GENE-UP and VERIFLOW for detection of microorganisms for the food industry; ETEST for manual measurement of minimum inhibitory concentration; API and RAPIDEC CARBA NP for identification of bacteria and manual antimicrobial susceptibility testing; BIOBALL for quantitative microbiological quality control; CHEMUNEX, a microbiology instrument; ENDONEXT for detection of endotoxins; TEMPO for fluorescence counting of bacteria; and Hybiome, a CLIA technology, as well as lab consultancy service and training modules. It has partnership with Boehringer Ingelheim and Evotec. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get bioMérieux S.A data using free add-ons & libraries
Get bioMérieux S.A Fundamental Data
bioMérieux S.A Fundamental data includes:
- Net Revenue: 3 980 M
- EBITDA: 948 M
- Earnings Per Share: 4
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-06-30
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
bioMérieux S.A News

bioMérieux receives FDA 510(k) Clearance for its VITEK® COMPACT PRO, a new ID/AST system to fight against antimicrobial resistance
MARCY L'ÉTOILE, France, March 18, 2025 /PRNewswire/ -- bioMérieux, a world leader in the field of in vitro diagnostics, announces the U.S. Food and Drug Administration (FDA) 510(k) clearance for VIT...


BioMerieux SA (BMXMF) Full Year 2024 Earnings Call Highlights: Surpassing Growth Targets and ...
Sales Growth: 10.3% in 2024, exceeding the revised guidance. Profitability Improvement: 20% increase at constant exchange rates. Free Cash Flow: EUR 330 million, nearly tripling from 2023. SPOTFIRE Sa...

bioMérieux Receives Health Canada Approval for the BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel
MONTREAL, Feb. 25, 2025 /CNW/ - bioMérieux, a world leader in the field of in vitro diagnostics, has achieved a significant milestone with the Health Canada approval of the BIOFIRE® SPOTFIRE® Respi...

bioMérieux Launches GENE-UP® TYPER,an Innovative Diagnostic Solution for Food Industries to Rapidly Analyze the Root Causeof Contamination of Listeria monocytogenes
Real-Time PCR* Solution Combines an Assay and a Web Application for Rapid Strain Characterization to Quickly Identify Root Cause Contamination Aiding in More Rapid Decision Making to Minimize Future R...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.